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Abstract 
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative 
disorder that primarily affects males who are carriers of a premutation of a CGG 
expansion in the FMR1 gene. In Asian populations, FXTAS has rarely been reported. Here, 
we report the case of a Japanese FXTAS patient who showed predominant executive 
cognitive deficits as the main feature of his disease. In contrast, the patient exhibited 
only very mild symptoms of intention tremor and ataxia, which did not interfere with 
daily activities. A gene analysis revealed that the patient carried a premutation of a CGG 
expansion (111 CGG repeats) in the FMR1 gene. The mRNA expression level of FMR1 in 
the patient was 1.5-fold higher than in controls. On brain MRI scans, fluid-attenuated 
inversion recovery images showed high-intensity lesions in the middle cerebellar 
peduncles and the cerebral white matter, with a frontal predominance. The present case 
extends previous notions regarding the cognitive impairment in FXTAS patients. 
Recognizing FXTAS patients with predominant cognitive impairment from various ethnic 
backgrounds would contribute to our understanding of the phenotypic variation of this 
disease. 
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Introduction 
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset 
neurodegenerative disorder that primarily affects male carriers of a premutation 
expansion, ranging from 55 to 200 CGG repeats, in the FMR1 gene [1, 2]. The main 
features of FXTAS are intention tremor and gait ataxia. Less distinctive symptoms include 
parkinsonism, peripheral neuropathy, and cognitive decline [3]. Here, we report the case 
of a Japanese patient with a CGG premutation expansion in the FMR1 gene, who 
presented with predominant executive dysfunction and cerebral white matter lesions on 
MRI. 
Case Report 
A 59-year-old Japanese male patient first noticed occasional gait unsteadiness at the age of 44 years. 
The symptoms remained stable for a decade. There is no family history of mental retardation or 
neurological disease. His birth and early development were unremarkable. The patient gradually 
exhibited various cognitive symptoms including slowness in initiation and completion of simple tasks, 
excessive sleepiness during daytime, and poor concentration. He was referred to our hospital at the age 
of 59 years. On admission, detailed neuropsychological examinations were performed, the results of 
which are shown in table 1. General intellectual function, determined by the Wechsler Adult 
Intelligence Scale-III and Mini-Mental State Examination, was moderately impaired. The patient 
demonstrated poor performance in executive cognitive function tasks, examined by the Trail Making 
Test, Wisconsin Card Sorting Test, and Stroop test. His Frontal Assessment Battery score was also very 
low. Visual-spatial perception and language skills were preserved, and there were no signs of mood 
disorder or anxiety. On neurological examination, the patient showed mild intention tremor with 
terminal kinetic movement. His handwriting was well preserved. He showed mild truncal ataxia but was 
fully ambulant. There was no ataxia in his limbs, and muscle tendon reflexes in the extremities were 
attenuated. In addition, there was no sign of autonomic failure. 
On brain MRI, fluid-attenuated inversion recovery images showed high-intensity lesions in the 
middle cerebellar peduncles (MCPs) (fig. 1a). Prominent cerebral white matter hyperintensities with a 
frontal predominance were also noted (fig. 1b, c). In addition, atrophy was observed in the cerebral 
cortex and cerebellar hemispheres. 
99mTc-ethyl cysteinate dimer single-photon emission computed 
tomography revealed hypoperfusion in the cerebellum and the medial temporal lobe. 
On the basis of these findings, we suspected that the patient suffered from FXTAS, although he 
exhibited minor motor symptoms and predominant cognitive symptoms. We determined the CGG 
repeat in the FMR1 gene using genomic DNA extracted from peripheral blood leukocytes as previously 
reported [4]. PCR analysis showed that the patient carried a premutation of a CGG expansion (fig. 2a). 
The size of the premutation determined by a fluorescent-sequencer method was 111 CGG repeats (fig. 
2b). We next examined the FMR1 mRNA expression level in peripheral blood. SYBR green real-time 
PCR assay was performed as previously reported [5]. In our patient, the mRNA expression level of the 
FMR1 gene, normalized to that of β-glucoronidase, was 1.5-fold higher than in 4 male healthy controls. 
Discussion 
According to diagnostic criteria [2, 3], the present case is defined as definite FXTAS, 
because the patient showed 2 clinical features (intention tremor and gait ataxia) as well as 
1 major radiological finding (MCPs). However, motor dysfunction due to ataxia and 
tremor was very mild and did not interfere with activities of daily life. In contrast, the 
patient showed prominent executive cognitive deficits as the predominant feature of his 
disease. Case Rep Neurol 2011;3:118–123 
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In recent years, cognitive impairments in FXTAS patients have increasingly been 
investigated [6–8]. The cognitive phenotype of FXTAS is characterized by fronto-
subcortical dementia with impairment of executive functioning [9, 10]. It is as yet 
unknown when cognitive impairment begins in relation to the neurological signs of 
FXTAS. Gonçalves et al. [11] reported the case of a 70-year-old patient with atypical 
FXTAS, who presented rapidly progressive dementia as the major symptom. We here 
showed that our Japanese FXTAS patient exhibited frontal and executive dysfunctions 
characterized by psychomotor slowness, bradyphrenia, distractibility as well as attention 
and concentration difficulties. Prominent hyperintensities in the cerebral white matter 
with a frontal dominance might be attributable to the development of these 
manifestations in the patient. These findings extend the previous notions regarding the 
cognitive impairment associated with FXTAS. 
Asian patients with FXTAS have rarely been reported in the literature. The exact 
reason for this is currently unknown. Recently, Ishii et al. [12] reported the first Japanese 
FXTAS patient who was initially diagnosed with essential tremor. Recognizing FXTAS 
patients with predominant cognitive impairment would contribute to our understanding 
of the disease’s phenotypic variation. Genetic testing should be considered in patients 
with unidentified causes of cognitive impairment, particularly when an MRI shows 
hyperintensities in the cerebral white matter and/or MCPs. 
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Table 1. Neuropsychological test results of the patient 
Test  0Result 
MMSE  023/30 
WAIS-III  
Verbal IQ  081 
Performance IQ  070 
Total IQ  073 
FAB  005/18 
Trail Making Test   
Part A  210 
Part B  744 
Stroop test   
Word  041 
Color  065 
Interference  024 
WCST  
Category achieved  000 
MMSE = Mini-Mental State Examination; WAIS-III = Wechsler 
Adult Intelligence Scale, third edition; FAB = Frontal Assessment 
Battery; WCST = Wisconsin Card Sorting Test. 
 
 
 
 
 
Fig. 1. MR images of the patient’s brain. a An axial fluid-attenuated inversion recovery image shows 
high intensities in the bilateral MCPs, as indicated by arrowheads. In addition, atrophy in the pons, 
MCPs, and cerebellum can be identified. b, c Prominently increased signal intensities in the cerebral 
white matter as well as diffuse cortical atrophy can be observed. 
 
 Case Rep Neurol 2011;3:118–123 
DOI: 10.1159/000328838 
Published online: 
May 24, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–680X 
www.karger.com/crn   
 
 
 
122
 
Fig. 2. Genetic molecular analysis of the FMR1 gene. a PCR-amplified genomic DNA samples from 
male control subjects (lanes 2–4) and the patient (lane 5) were run on a 2% agarose gel and stained 
with ethidium bromide. In the patient’s sample (lane 5), the PCR product containing the premutation 
of CGG repeats is shown (arrow). The DNA size marker (M, lane 1) is a mixture of λ-HindIII and 
ΦX174-HaeIII digests. b The PCR product from the patient was further analyzed using an ABI3130x 
sequencer. The size of the premutation determined using GeneMapper software (version 4.0, Applied 
Biosystems) was 514 bp (arrowhead), which corresponds to approximately 111 CGG repeats. 
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